Table 1.
Clinical and demographic characteristics of men of working age diagnosed with localised low and intermediate-risk prostate cancer stratified by initial treatment strategy, and matched prostate cancer-free men in PCBaSe, 2007–2016
| Active surveillance (%), n=5361 |
Radical prostatectomy (%), n=8938 | Radiotherapy (%), n=1603 |
PCa-free men (%), n=63 464 |
|
| Age at diagnosis (years) | ||||
| Median (IQR) | 60 (57–63) | 60 (56–62) | 61 (58–63) | 60 (56–62) |
| Year of diagnosis | ||||
| 2007–2009 | 1033 (19) | 3008 (34) | 611 (38) | 18 203 (29) |
| 2010–2012 | 1481 (28) | 2748 (31) | 503 (31) | 18 595 (29) |
| 2013–2016 | 2847 (53) | 3182 (36) | 489 (31) | 26 666 (42) |
| Education | ||||
| Low (0–9 years) | 899 (17) | 1633 (18) | 344 (21) | 13 228 (21) |
| Middle (10–12 years) | 2416 (45) | 3844 (43) | 751 (47) | 28 206 (44) |
| High (>12 years) | 2037 (38) | 3448 (39) | 507 (32) | 21 825 (34) |
| Missing | 9 (0) | 13 (0) | 1 (0) | 205 (0) |
| Income* | ||||
| 1%–20% | 759 (14) | 1292 (14) | 312 (19) | 12 701 (20) |
| 21%–40% | 914 (17) | 1584 (18) | 341 (21) | 12 693 (20) |
| 41%–60% | 1112 (21) | 1751 (20) | 374 (23) | 12 697 (20) |
| 61%–80% | 1231 (23) | 1980 (22) | 309 (19) | 12 695 (20) |
| 81%–100% | 1345 (25) | 2331 (26) | 267 (17) | 12 678 (20) |
| Prior sick leave | ||||
| No | 4937 (92) | 8218 (92) | 1425 (89) | 58 155 (92) |
| Yes | 424 (8) | 720 (8) | 178 (11) | 5309 (8) |
| Risk category | ||||
| Low risk | 4569 (85) | 3839 (43) | 678 (42) | |
| Intermediate risk | 792 (15) | 5099 (57) | 925 (58) | |
| Clinical T stage | ||||
| T1 | 0 (0) | 0 (0) | 1 (0) | |
| T1a | 173 (3) | 30 (0) | 3 (0) | |
| T1b | 38 (1) | 29 (0) | 7 (0) | |
| T1c | 4598 (86) | 6321 (71) | 1005 (63) | |
| T2 | 552 (10) | 2558 (29) | 587 (37) | |
| Serum PSA (ng/mL) | ||||
| PSA<4 | 1405 (26) | 1739 (19) | 191 (12) | |
| 4≤PSA<10 | 3507 (65) | 5744 (64) | 1065 (66) | |
| 10≤PSA<20 | 443 (8) | 1443 (16) | 344 (21) | |
| Missing | 6 (0) | 12 (0) | 3 (0) | |
| Gleason Grade Group (biopsy) | ||||
| GGG 1 | 4956 (92) | 4504 (50) | 816 (51) | |
| GGG 2 | 344 (6) | 3460 (39) | 568 (35) | |
| GGG 3 | 49 (1) | 970 (11) | 219 (14) | |
| Missing | 12 (0) | 4 (0) | 0 (0) | |
*Based on the income distribution of prostate cancer-free men.
GGG, Gleason Grade Group; PCa, prostate cancer; PCBaSe, Prostate Cancer Data Base Sweden; PSA, prostate-specific antigen.